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lial cells, or sarcomas if they are mesenchymal in origin (2). The emphasis given here to the dassification of tumors as benign or malignant is due to the implications of the diagnosis of malignancy because it affects the epidemiology of the disease, the dinical and therapeutic approaches, and the interpretation of experimental data.
The most significant malignant neoplasm in the human breast is the adenocarcinoma. The understanding of this disease requires a multiprong approach that encompasses epidemiologic and clinical data, as well as adequate experimental systems for evaluating risk assessment or for testing chemopreventive and therapeutic agents.
Breast cancer is the most frequent spontaneous malignancy diagnosed in women in the western world. In the United States alone, 182,000 new cases were diagnosed in 1994; its incidence has been increasing for several decades (3) (4) (5) . Data from continuously operating cancer registries, such as the one in the state of Connecticut and the Surveillance, Epidemiology, and End Results (SEER) program established by the National Cancer Institute in 1973 (which collects data from nine population-based cancer registries covering about 10% of the US population), reveal that the age-adjusted incidence of breast cancer rose at a rate of 1.2%/year from 1940 to 1980; it rose even more steeply in the next 7 years, reaching a peak of 112.4 cases/100,000 women in 1987, although it decreased to 104.6 cases/100,000 women by 1989 (3) (4) (5) . The increased incidence of cancer has been pardy attributed to an improvement in early detection, as indicated by the progressively increased percentage of patients with early stage (0 to I) disease (from 45 .2% in 1985-1986 to 53 .1% in 1991) and decreased percentage of patients in stage II and III disease (6) . Early diagnosis has improved the rates of cure and prolonged survival; however, stage-specific survival rates have increased only slightly since the mid1970s, and breast cancer remains only second to lung cancer as a cause of death, causing 46 ,000 deaths in 1994 (3) (4) (5) .
From all experimental systems available for the study of mammary cancer, rodent models have been particularly useful, mainly because spontaneous mammary tumors are frequently observed in long-term studies (7) . They are the most common hormonedependent spontaneous neoplasms developed in several strains of female rats; their development, which increases with aging, is attributed to hormonal imbalances such as the constant estrous that occurs in old Sprague-Dawley rats (7) (8) (9) ; JT Stevens, personal communication). In mice, spontaneous mammary tumors are either linked to the infection of females with an exogenous mouse mammary tumor virus (MMTV) or a less virulent endogenous provirus (9) (10) (11) . Nevertheless, mammary tumors are also hormone dependent, as initially demonstrated by Lathrop and Loeb, who reported that ovariectomy at an early age either inhibited or delayed the appearance of mammary tumors in outbred mice (9) .
The susceptibility of the rodent mammary gland to develop neoplasms has made this organ a unique target for testing the carcinogenic potential of specific chemicals. Several carcinogens that induce mammary tumors in both mice and rats have been extensively studied in both species (9, . Tumors induced by administration of chemical carcinogens constitute useful tools for dissecting the multistep process of carcinogenesis, which involves initiation, promotion, and progression, and serve as a baseline for testing the carcinogenic potential ofchemicals in risk assessment (7, 37) . Chemically induced mammary tumors are, in general, hormonedependent adenocarcinomas. Their incidence, number of tumors per animal, and tumor type are influenced by the age of the host at the time of carcinogen exposure, reproductive history, endocrinologic milieu, and diet, among other factors. These factors, in turn, influence the development and degree of mammary gland differentiation (38) (39) (40) (41) , which are subject to a multiplicity of endocrine stimulatory and inhibitory influences from embryogenesis onward (39, 40, (42) (43) (44) . If these influences are not exerted in proper temporal, sequential, and quantitative relationships, normal development, differentiation, and function are adversely affected (41) . The development of the mammary gland, in turn, cannot be separated from its aging, a process that markedly influences the incidence of spontaneous tumors in all strains of rats (8, 45, 46) , as well as in mice infected with MMTV (10) .
The ideal animal tumor model should mimic the human disease (23, 47) by providing a model for ascertaining the influence of host factors on the initiation of tumorigenesis, mimicking the tumorigenic response elicited under specific age and reproductive conditions, and determining the response of the tumors induced to chemotherapy. The use of experimental models of mammary carcinogenesis in risk assessment requires that the influence of ovarian, pituitary, and placental hormones, as well as overall reproductive events, and age at menarche and menopause are taken into consideration because they are important modifiers of the susceptibility of the organ to neoplastic development (9, 41, 48) . Several species such as rodents (9, 41) , dogs (49) , cats (50) , and monkeys (51) have been evaluated for these purposes; however, none of them fulfill all the criteria specified above. Rodents, however, are the most widely used models (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) 41, 47, 52) . Therefore, this work will discuss various aspects of the rodent model such as 1) the normal anatomy and development of the mammary gland during reproductive events and aging; 2) the influence of reproductive, aging, and nongenotoxic factors on tumor development; 3) experimental genotoxic-induced rodent mammary tumor models; 4) modifiers of susceptibility of the gland to neoplasia; and 5) impact of hormones and growth factors on mammary carcinogenesis. In addition, current knowledge on human breast cancer will be briefly reviewed to establish a unifying concept between human and rodent carcinogenesis.
Mammary Gland Development
Anatomy of the Mammary Gland Gross anatomy. The mammary gland, whose function is the secretion of milk for the nourishment of the offspring, adapts to this function primarily by developing a number of glands adequate for sustaining the number of newborns that are characteristic for a given species (41, 47, 53) . In both rats and mice, the mammary glands are aligned ventrolaterally along the mammary or milk lines from the cervical to the inguinal regions. The only externally visible portion of the mammary gland in the female is the nipple, a cutaneous structure located ventrolaterally, and from which the rest of the mammary gland extends dorsolaterally as flat subcutaneous sheets of fibroadipose tissue (40, 53) . Male mice have no nipples, and they usually have four pairs of rudimentary glands consisting of major branching ducts with no alveoli, primary ducts, or openings to the exterior (53) . Female mice, on the other hand, have five pairs of mammary glands, one cervical, two thoracic, and two abdominal-inguinal pairs. The female rat has six pairs, the fifth and sixth pairs being located in the inguinal region. Except for the difference in total number of mammary glands in the females, the anatomic location and distribution of these paired organs is similar between these two species; therefore, the descriptions below apply indistinctly to both, unless otherwise specified. No further description will be done of the mammary gland in males because it is an atrophic organ that rarely gives origin to spontaneous tumors or is the subject of carcinogenicity studies.
The size and distribution of the mammary glands vary markedly as a function of sex, age, hormonal stimulation, and reproductive condition (23, 39, 40, 54) . Classical descriptions of mammary gland distribution apply to the glands of fully mature parous females in which the first pair, or cervical mammary glands, extend cranially to the parotid and mandibular salivary glands and laterally along the medial aspect of the forelimb, reaching the interscapular fat pad. The second and third pairs are located in the thoracic region, extending laterally and dorsally from the nipples, which are medially located. The two pairs of abdominal-inguinal glands in the female mouse and the three pairs of abdominoinguinal glands in the female rat are in Comparison of gland area and number and complexity of branching at 15 (x3.9), 30 (x3.4), and 55 (x5. 6) days of age. n, nipple. Whole mount preparations, toluidine blue (x3).
Environmental Health Perspectives * Volume 104, Number 9, September 1996Review -Russo and Russo TEB n 00 ME w v A B C Figure 2 Schematic representation of the fourth (abdominal) mammary gland of a 55 day-old virgin female rat The gland was divided into three zones: A, proximal to the nipple (n), contains more numerous lobules type 1 (lob). Zone B, medial, encompasses the lymph node (LN). Zone C, distal to the nipple, contains the majority of actively growing terminal end buds (TEB); alveolar buds (AB) and terminal ducts (TD) are also present From Russo and Russo (20) . close continuity, extending medially in the pubic region, caudally to the perianal region, and laterally onto the medial aspect of the hindlimbs (40, 47, (53) (54) (55) . Microscopic anatomy. The basic architecture of the mammary gland has been extensively described as a complex structure composed of parenchyma and stroma (40, 42, 44) . The understanding of the structure of the gland requires the study of the complete organ in whole mount preparations ( Fig. 1 ) combined with histological sections representative of specific areas of the same because different topographic areas contain structures that differ in their morphology, cell kinetic characteristics, hormone responsiveness, and carcinogenic potential (23) .
The parenchyma consists of one or two major lactiferous ducts that grow from the nipple into the surrounding fat pad. The growth of the mammary gland occurs as the result of a combined process of lengthening of major ducts in a straight fashion in the areas doser to the nipple, which in the rat has been called zone A (Fig. 2) (39, 40, 54, 55) . A progressive dichotomous and sympodial branching of smaller ducts and lateral buds occurs more frequently in the middle third of the gland (zone B). The portion of the gland opposite to the nipple (zone C) contains the most actively growing terminal ductal structures, the terminal end buds (TEBs) (Fig. 2) (15, 22, 23, 39, 40, 42, 53) . The mammary ducts are tubular structures with walls composed of two main cell types, an internal layer of epithelial cells lining the lumen and an external and discontinuous layer of myoepithelial cells resting on the basement membrane (Fig. 3,4 ) (40) . Both the thickness of the epithelial layer and its degree of differentiation vary as a function of the specific structure in which they are located. Major ducts tend to be lined by a single or pseudostratified layer of low columnar or cuboidal epithelial cells. The luminal border is fringed with short, blunt microvilli. Adjacent cells interdigitate and are joined by well-developed junctional complexes (42, (56) (57) (58) . TEBs, on the other hand, are lined by a multilayered epithelium composed of large cuboidal cells exhibiting a high rate of cell proliferation ( Fig. 5) (40) . In the mouse, the end bud consists of four to six layers of cuboidal epithefium. On the basal surface of the end bud beneath the basal lamina are the cap cells (5$ ). These cells lack differentiated features: they lack cytoplasmic polarity, they do not form cell junctions, and they do not contain highly organized cytoskeletal elements. These cells are interpreted to represent a pluripotent stem cell population, capable of differentiating into both mammary ductal and mammary myoepithelial cell types (42) . Ultrastructurally, the cells composing the TEBs have been described as intermediate cells (6, 57) due to the moderate electron density of the nudeus and the cytoplasm, in contrast with the other two cell types described in both the rat and the mouse mammary glands, the dark and the light cells (42, (57) (58) (59) (60) . Intermediate cells (Fig. 3-6 ) have a large round or oval nucleus and an abundant cytoplasm rich in organelles, but show almost no secretory activity. In contrast, dark cells ( Fig. 3-6 ), which are more numerous in ducts and secretory alveoli, have smaller and convoluted nudei and contain abundant cytoplasm rich in ribosomes, Golgi complexes, lipid droplets, and secretory vacuoles (40) . The external layer or myoepithelium is located between the epithelial layer and the basal lamina (Fig. 3,6 ). Myoepithelial cells appear moderately electron dense due to the presence of thick bundles of tonofilaments and myofibril-like bundles of actin and myosin in the cytoplasm, a characteristic that these cells share with smooth muscle fibers. Their plasma membrane contains numerous pinocytotic vesicles and is attached to the basal lamina by hemidesmosomes (Fig. 3,6 ) (40). The basement membrane on which the epi-myoepithelial complex rests is composed of a bilayered basal lamina: the lamina lucida, in dose contact with the myoepithelium, and the lamina densa, which forms a continuous sheath between the lamina lucida and the stroma (42, 48, (61) (62) (63) . Volume 104, Number 9, September 1996 * Environmental Health Perspectives Review e Mammary gland neoplasia in rodent studies 
Prenatal and Postnatal Development
The developmental and functional states of the mammary gland are subject to a multiplicity of genetically determined endocrine stimulatory and inhibitory influences from early embryogenesis through the senescence of the individual. Studies of the sex differences in mammary gland histogenesis indicate that the rodent mammary rudiment is sensitive to the influences of gonadal steroids during the prenatal stage (44, 64, 65) . In mice, sexual differentiation of the gonads occurs on the late 13th day of gestation, after which the testes start to produce androgens in the male embryo. On the 14th day, the sexual phenotype of the mammary gland is determined (44) . At this time, the male mammary bud becomes constricted at its epidermal junction and ultimately becomes completely detached. X-ray destruction of the fetal testes on the 13th day of gestation causes the mammary bud of the male to remain attached to the epidermis and the duct primordia to ramify similarly to the primordia of the female. Testosterone injections into pregnant animals cause the mammary buds of female embryos to undergo male-type development (44) . The milk-fed newborn is exposed to a rich source of growth factors; these factors might play important roles in the growth and development of the mammary gland (66) . One of the principal growth factors present in milk is epidermal growth factor (EGF), which is an important regulator of mouse mammary epithelial cell proliferation and differentiation both in vivo and in vitro (67) .
In the Sprague-Dawley rat, the mammary gland evolves from a primary main lactiferous duct; it branches into multiple secondary ducts, whose length and the number of branches it originates increase with aging of the animal (Fig. 1) . By the second week of postnatal life, the ducts have further sprouted to a sixth generation of branches, which end in dub-shaped TEBs composed of three to six layers of medium-sized epithelial cells (Fig. 5,6 ). The number of TEBs is maximal when the rats are 21 days old; after this age, TEBs begin to cleave into three to five smaller buds or alveolar buds (ABs). The progressive differentiation of TEBs into ABs is accentuated by each estrous cycle, which starts when the animals are 30-42 days old (39) . In the nonpregnant female, the development of the mammary gland is rigorously controlled by the ovary. Ovariectomy causes regression of end buds and cessation of growth (42 (68) (69) (70) (71) . In general, estrogens are responsible for growth of mammary ducts and progesterone is necessary for lobuloalveolar growth in the mouse (72) ; however, a direct mitogenic effect of estrogens on the mammary gland has not been clearly demonstrated (73) . A postulated mechanism is that estrogens stimulate secretion of growth factors such as EGF (74) or other growth factors of mammary or extramammary origin that might sensitize the mammary gland to mitogenic factors (73, 75 (76, 77) . The mammogenic effects of ovarian steroids are largely dependent on the integrity of the pituitary gland, because the effects of estrogen and progesterone cannot be demonstrated in hypophysectomized animals (78) . Ductal elongation and branching that occurs during puberty is positively regulated by ovarian estrogens and pituitary GH, which in turn might act through its local mediator, insulin-like growth factor I (IGF-I) (66) . Furthermore, in the rat, estrogens stimulate the secretion of pituitary PRL; this hormone, rather than progesterone, appears to regulate the lobuloalveolar development of the mammary gland and exerts a direct effect on the growth of the mammary parenchyma and epithelium (67, 79) .
Mammary Gland Development during Pregnancy
Pregnancy represents a completely novel endocrinologic experience to the female organism. The fertilized egg becomes a new endocrine organ soon after conception. The developing blastocyst and the placenta represent a rich source of hormones and growth factors, which, in conjunction with fetal secretions, enter the maternal bloodstream, thus influencing multiple target organs (39) . In the first pregnancy of a young female rat, there are six pairs of mammary glands that differ in their degree of development, depending upon the topographic location of each specific gland and of the distance between the location of a given parenchymal structure and the nipple (Fig. 2) (39, 80) . Gland development is also influenced by other factors, such as the number of ovulatory cycles that have occurred after the initiation of the ovarian function, diet and specific genetic characteristics of the animal (39, 81, 82) .
At mating, the mammary glands contain a large proportion of TEBs, which are more numerous in the zone C of the glands (Fig. 2,6 ,7A,8A). They are also more numerous in thoracic than abdominal mammary glands. There are also ABs, but few lobules are present (39) . Cervical stimulation at mating increases PRL levels, which in turn increase the number of ovarian luteal LH receptors, thus enhancing steroidogenesis. Early in pregnancy, the combined influences of ovarian estrogen, progesterone, and inhibin (68, 71) , with the production of rat chorionic gonadotropin (rCG) and rat placental lactogen (rPL) by the developing embryo, contribute to stimulate the mammary glands to undergo active cell proliferation. Greater activity is observed in TEBs, which rapidly cleave to form ABs, thus diminishing their number. ABs, in turn, progressively differentiate into lobules (39) . In early pregnancy, the estrogen receptor content of the mammary gland becomes significantly higher than that of virgin rats (83) . Pituitary relaxin, which plays an important role in the development of the nipples during the second half of pregnancy, also influences the development of lobules and the lactational capacity of the mammary glands (84) .
During the gestational process, immunocytochemical reactions with antilaminin and type IV collagen antibodies reveal that the basement membrane remains intact around the newly formed lobules. Myosin-positive myoepithelial cells are attenuated and discontinuous in the alveoli, while they are prominent in the main ducts (62, 63) . The alveolar epithelium exhibits positive immunoreactivity with inhibin antibodies, which reaches its peak by the 15th day of pregnancy. Thereafter, the reaction becomes more intense in the perilobular stroma (85, 86) . At the end of pregnancy, the mammary gland is almost completely composed of densely packed lobules (Fig. 7B,8B ). They Volume 104, Number 9, September 1996 . Environmental Health Perspectives (16) (17) (18) . The profound morphological and cell kinetic differences observed between young and old virgin rats and between old virgin and multiparous rats are not the result of differences in circulating hormonal levels because the levels of PRL and estradiol are similar in the three groups of animals studied (89) . However, with senescence, the circulating hormone levels Environmental Health Perspectives * Volume 104, Number 9, September 1996 are markedly altered compared to young females (90) ; aged female Sprague-Dawley rats have significantly lower FSH, estradiol, and progesterone levels than young cyding females. PRL levels on the other hand have been shown to be elevated (91) . These changes in hormone levels manifest themselves with a lengthening of cycle duration as a precursor to acyclicity that occurs in aged females (92, 93) . The binding of estrogen to receptors in the pituitary, hypothalamus, uterus, and mammary gland is decreased in aged noncycling rats (94) (95) (96) (97) (64, 65, 100, 101) . Despite the complexity of the endocrine systems, hormones can be classified into two major categories: those that are regulated by the central nervous system (CNS), namely, the hypothalamus-anterior pituitary system and those whose production is, for the most part, independent of the CNS, i.e., hormones of the peripheral system, which are regulated more directly by their own effects (98).
Hypothalamus-Anterior Pituitary System
The development, anatomy and physiology of the pituitary gland and its relationship with the hypothalamus have been extensively studied during the last two decades, especially in experimental animals, with the rat being the animal most frequently used (98, 102) . Although many pituitary hormones have a common evolutionary origin, extrapolations of findings obtained in different animal species to human conditions are difficult, especially due to differences in the development and function of the pituitary gland occurring with aging, a period in life of extreme importance in the development of mammary neoplasms. Senescence is frequently associated with pituitary hyperplasia and development of adenomas in various strains of rats, whereas in humans the anterior lobe undergoes a slight or moderate involution, the pituitary weight decreases, and the incidence of adenomas is unchanged or slightly reduced (102) . There are also wide differences in the morphology of the gland during development among various strains and among species. A description of the anatomy and physiology of the hypothalamus-pituitary system is beyond the scope of this review; therefore, only issues of essential importance for the comprehension of its interaction with the development of the mammary gland and its neoplasms will be attempted here. Despite interspecies differences, it is possible to establish a common pattern for this system (98, 102 ( 106) pituitary tumors (107) Reproductive aging is the result of ovarian failure Reproductive aging is the result of neuroondocrine rather than neuroendocrine failure ( 108) failure (107) Ovarian failure is characterized by the depletion of Neuroendocrine failure is characterized by a decline the fixed supply of primary ovarian follicles (109) of hypothalamic neurosecretory activity resufting in an inability to stimulate the preovulatory gonadotropin (LH) surge essential for ovulation (110) At menopause, estrogen and progesterone Loss of the preovulatory surge leads to an arrested secretion decline and pituitary gonadotropin ovarian follicular development, which results in secretion rises (111) persistent rather than cyclic estrogen secretion ( 112) Rising gonadotropin (FSH, LH) secretion in Exposure to endogenous estrogens occurs for a postmenopausal women is evidence of intact prolonged period of time creating an environment hypothalamic function (113 PRL is capable of exerting a direct effect on the growth of the mammary parenchyma and epithelium (79) . Gonadotropins have a significant influence on ovarian function; the secretion of FSH promotes the development of the Graafian follicles. LH is also required to bring the follides to full maturity and to stimulate estrogen secretion. The corpus luteum, itself an endocrine gland, under the influence of LH secretes estrogen, progesterone, and inhibin (69) . Finally, GH is also involved in mammary gland development and function. Although its exact mechanism of action is unclear, it directly stimulates duct growth in hypophysectomized-ovariectomized rats; however, the presence of estrogen is also necessary to evoke normal duct development. The prevailing metabolic condition of an individual animal or human may significantly influence mammary gland response to hormones. It has been demonstrated that estrogen and progesterone, when given with long-acting insulin, stimulate considerable mammary duct growth in hypophysectomizedgonadectomized rats (72) . The growth-supporting effect of insulin can be enhanced by giving thyroxine. A synergistic effect of 11- desoxycorticosterone and estrogen on mammary duct growth has been observed in the ovariectomized virgin mouse. The various endocrine secretions influencing mammary gland development and function are summarized in Table 3 . The maintenance of regular cycling events is important in rodents and humans for normal reproduction (115) . There are remarkable differences in endocrine physiology between estrual and menstrual animals ( 
Spontaneous Rodent Mammary Tumors
Spontaneous mammary tumors are frequently observed in long term rodent studies (116) . In mice, the development of spontaneous mammary tumors is linked to the infection of female mice with either an exogenous MMTV or a less virulent endogenous provirus. A third strain of MMTV transmitted through the milk and through the germ line has also been identified in the European mouse strain GR (9) (10) (11) . The exogenous MMTV is an RNA virus first recognized to be transmitted through the milk of A and C3H strain mothers, the Bittner factor (117). DBA and RIII are also inbred strains of mice that harbor the highly oncogenic MMTV transmitted through the milk. Foster-nursed neonatal mice (i.e., C3Hf or DBAf) become free of the milk-transmitted MMTV although they retain the genetically transmitted MMTV, which induces mammary tumors late in life (9) (10) (11) . In high-incidence strains of mice, tumors develop as a multistep process initiated in preneoplastic lesions, the hyperplastic alveolar nodules, which evolve from pregnancy-dependent to pregnancy-independent adenocarcinomas (9) . Nulliparous mice develop a low incidence of mammary tumors. Out of a total of 1361 female B6Cf /CrlBR mice, only 5 adenomas (0.4%), 4 Abroadenomas (0.3%), 10 adenocarcinomas (0.9%), and 7 carcinomas (0.6%) developed by the end of a 24-month follow up (118) . Some mammary tumors that develop in females of susceptible strains, such as C3H, A, DBA, 020, CBA, and certain sub-strains of Balb/c, are strongly hormone dependent in terms of their initiation. Multiple pregnancies enhance tumor development, and final tumorigenic response is greater in multiparous than in nulliparous animals. In RIII, BR6, DD, and GR mice, mammary tumors develop during the first pregnancy but they regress during lactation. In some strains of mice, the growth of mammary tumors is stimulated by chronic administration of estrogens, certain steroidal contraceptives, progesterone, PRL, and epidermal growth factor (EGF) (9), whereas hormone deprivation, induced by hypophysectomy, ovariectomy, ovariectomy-adrenalectomy, and syalidectomy suppress mammary carcinogenesis (9) .
In the rat, the majority of spontaneously developed tumors, with the exception of leukemia, are neoplasms of endocrine organs or of organs under endocrine control. Spontaneous mammary tumors develop in females of various strains of rats such as August, Albany-Hooded, Copenhagen, Fisher, Lewis, Osborne-Mendel, SpragueDawley, Wistar, and Wistar/Furth (9, 45, 116, (119) (120) (121) . Mammary tumors are third in incidence among spontaneous tumors found in the Fisher 344 rat used in the National Cancer Institute/National Toxicology Program (NCI/NTP) carcinogenicity bioassays (116) . They are predominantly benign tumors, i.e., fibroadenomas, fibromas, and more rarely adenomas. Malignant tumors such as adenocarcinomas are rare, although they are the most frequent tumors induced by chemical carcinogens (24, 47) . The development of spontaneous tumors varies as a function of strain, age, and endocrine influences. Mammary gland tumors develop in older females; they are more frequent in multiparous than in nulliparus rats. As in mice, hormone withdrawal inhibits tumor development in rats. Hormone supplementation, such as chronic administration of estrogens, increases the incidence of adenocarcinomas, whereas chronic administration of prolactin or of growth hormone stimulates benign tumor growth (9) . The long latency period for spontaneous tumor development, up to 2 years in susceptible strains to develop a 50-70% tumor incidence, limits the usefulness of this model for experimental studies.
Experimental Genotoxicinduced Rodent Mammary Tumor Models Chemicaly Induced Mammary Tumorigenesis
The potential of chemicals to induce cancer was recognized almost two centuries ago as an occupational disease when high incidence of skin cancer was linked to exposure to coal tar (2). Although it has not been proven that human breast cancer is caused by a given chemical or physical genotoxic agent, the human population is exposed to a large number of environmental chemicals such as polycyclic aromatic hydrocarbons, nitrosoureas, and aromatic amines, compounds that have been demonstrated to be carcinogenic in in vivo experimental animal models and have been shown to induce mutagenesis and neoplastic transformation of human breast epithelial cells in in vitro models (122) . Although a specific etiologic agent or the conditions that might explain the initiation and progression of breast cancer in humans have not been identified, experimental animal models have proven to be useful tools for answering specific questions on the biology of mammary cancer relative to their validity to the human disease (60) , as well as for assessing the risk for breast cancer posed by toxic chemicals (7, 37) . In vivo experimental animal models provide information not available in human populations: they are adequate for hazard identification, dose-response modeling, exposure assessment, and risk characterization, the four required steps for quantifying the estimated risk of cancer development associated with toxic chemical exposure (7) . The use of experimental models of mammary carcinogenesis in risk assessment requires that the influence of ovarian, pituitary, and placental hormones, among others, as well as overall reproductive events, are taken into consideration because they are important modifiers of the susceptibility of the organ to neoplastic development (9, 41, 44) .
Chemically induced mammary tumors develop by a multistep process. The initial step is a biochemical lesion caused by the interaction of the carcinogen with cellular DNA. In this interaction the DNA is damaged; if the damage is not repaired efficiently, the result is a mutation, a chromosomal translocation, an inactivation of regulatory genes, or more subtle changes not well identified as yet. Neoplastic development requires that the lesion becomes fixed, aided by cell proliferation, and progresses to a third stage of autonomous growth, which results in cancer when the lesion acquires the capacity to invade and metastasize (23) . Several carcinogens that induce mammary tumors in rodents have been identified and extensively studied for more than 50 years in mice and for more than 30 years in rats (9) . In mice, mammary carcinomas have been induced with 3,4-benzopyrene, 3-methylcholanthrene (MCA), 1,2,5,6-dibenzanthracene, 7,12-dimethylbenz(a)anthracene (DMBA), and urethane in strains of low spontaneous mammary cancer incidence. Most of the mammary tumors induced in mice by chemical carcinogens are adenoacanthomas and type B adenocarcinomas. They develop after a relatively long period of time, and their induction requires multiple applications. Enhanced tumorigenicity has been obtained with prolonged hormonal stimulation; however, the hormone responsiveness of chemically induced mammary tumors in mice has not been as thoroughly studied as it has been in the rat (9, 23, 60) .
In rats, DMBA, MCA, 2-acetylaminofluorene, 3,4-benzopyrene, ethylnitrosourea, butylnitrosourea, and N-methyl-Nnitrosourea (MNU) have been extensively used as mammary carcinogens, with DMBA and MNU used most frequently (9,12-14, 23,41,60) . The majority of rat mammary carcinomas induced by either DMBA or MNU are hormone dependent. Maximal tumor incidence is elicited when the carcinogens are administered to young virgin females with an intact endocrine system (Table 5 ). These models of hormone-dependent tumors constitute useful tools for dissecting the multistep process of carcinogenesis and serve as a baseline for testing the carcinogenic potential of chemicals in risk assessment (7).
Radiation-induced Mammary Tumorigenesis
Ionizing radiation is probably the most widely acknowledged and studied human carcinogen (47) . Exposure to radiation, either accidentally or for therapeutic reasons, has long been associated with a greater incidence of neoplasms, namely, hematopoietic, gonadal, and breast (123) . The female breast is one of the tissues with the highest sensitivity to radiation carcinogenesis (124) . Breast cancer developed in irradiated women shows a strong association with young age at the time of exposure, an association not observed in irradiated rodents (123) but similar to what has been observed in chemically induced mammary carcinogenesis in rats (21, 38, 123) . Since controversy exists concerning the shape of the dose-response curve, the effects of fractionated irradiation, and the effect of low levels of radiation (125) , animal studies are necessary to address these issues. The rat model has been widely used in this regard, mainly since the demonstration in the early 1950s that a single supralethal dose of X rays to female Holtzman rats (a Sprague-Dawley stock) maintained by temporary parabiosis induced an increased number of benign and malignant mammary tumors within 6 months of exposure (47, 126) . Sublethal doses of different types of radiation, including X rays and neutrons, have been shown to induce mammary tumor development, often within a year, with linear dose-effect relationships for neutrons over the total dose range and for X rays down to dose levels of 0.2 Gy (127) (128) (129) . Irradiation of animals with fractionated doses of y-radiation has resulted in linear-quadratic doseresponse curves (130) . Although most studies have used whole-body irradiation, localized irradiation also induces mammary tumors in the rat within the irradiated field. This effect also occurs in women, but reportedly not in several other animal species studied, e.g., mice, dogs, and guinea pigs (127, 128, 131) . In rats, mammary carcinomas can be induced by whole-body or segmental radiation with either X rays, g rays or neutrons (9, 47 (23) .
Ovariectomy completely prevents, and estrogen treatment enhances, radiationinduced mammary tumor formation (47, 134 (5, 123, 143) . Among the endogenous factors, early parity, defined as completion of a first full term pregnancy before age 24, has been identified as a protective factor (5, 22, 144, 145) . Very little is known, however, about the time of initiation of the carcinogenic process or what agent(s) cause it. The facts that early full-term pregnancy is protective (5), and that a higher incidence of mammary carcinomas has been reported to develop in women exposed to ionizing radiations at a young age (123, 146) but not after pregnancy and lactation (22, 60) strongly suggest that, in the human female, the period between menarche and first fullterm pregnancy might be critical for the initiation of breast carcinogenesis. However, the precise time of initiation of the neoplastic process is not known. Regarding the site of origin of mammary neoplasms, there is evidence that tumors originate in the intralobular terminal ductal lobular unit (TDLU) or lobule type 1, the most undifferentiated structure present in the breast of nulliparous women (23) . Correlative studies have shown an equivalence between the TEB of the young virgin rat mammary gland and the TDLU-lobule 1 of the woman's breast in their carcinogenic potential (23, (147) (148) (149) (150) . Since human data are still insufficient for drawing a complete picture of the pathogenesis of breast cancer, adequate experimental systems mimicking the human disease are needed for addressing specific questions whose answer would allow one to elucidate (1) the influence of host factors on the initiation of the neoplastic process, (2) to determine whether the susceptibility of the human breast to undergo neoplastic transformation varies with age and reproductive history, and (3) to determine whether the susceptibility of the breast can be decreased through modifications of biological and physiological conditions of the host. We consider the model of rat mammary gland carcinogenesis to be the one that more dosely fulfills the above conditions. Mammary tumors induced in rodents by chemical carcinogens have been widely studied and are useful models of mammary carcinogenesis (16, 17, 24, 26, 28, 47, 52, (151) (152) (153) (154) . The objective of this review is to compare side by side what we know about the pathology of breast cancer in both humans and the rat model system to establish a solid basis for comparison and extrapolation of knowledge from animal to human. A comparative analysis will not only further our understanding of the biology of the human disease but will also highlight the gaps in knowledge that have to be filled in both systems. The two most widely used experimental systems of mammary tumorigenesis are the induction of rat mammary tumors by administration of either the indirect acting polycyclic hydrocarbon DMBA, given intragastrically (ig) to Sprague-Dawley rats (28) and the direct acting carcinogen MNU, given intravenously (iv) or subcutaneously (sc) to Sprague-Dawley or Fischer 344 rats, respectively (155, 156 (38, 157) . MNU, given in a single iv dose of 25 or 50 mg/kg body weight, yields tumors with similar latency and incidence (157) . In a comparative study between the carcinogenic potential of DMBA administered ig at a dose of 20 mg and MNU, given iv at a dose of 50 mg/kg, it was demonstrated that both induce approximately equal tumor incidence and number of tumors per animal with approximately equal latency, but a somewhat greater percentage of MNU-induced tumors are histologically malignant (32) .
For the study of modulating factors, especially when short-term studies are performed, it has been found that both tumor latency and tumor histological type are the most sensitive and reliable end points. Tumor latency is, in general, inversely related to carcinogen dose, whereas the overall tumor incidence and the number of malignant tumors per animal are directly related, especially when relatively early end points are used. No such relationship has been found for benign tumors (32) . The (Table 7) (60). These two indices are very high at the tip of both TEBs and TDs and decrease toward the ductal or proximal portion of the gland; however, TEBs have higher overall proliferative activity than TDs. Both mitotic index and DNA-LI are even lower in ABs and lobules (17, 19) . TEBs are also characterized for having the highest growth fraction, which progressively diminishes in the more differentiated ABs and lobules (19) . By using these cell kinetic parameters, we have calculated the rate of cell loss in each one of the compartments of the mammary tree. Interestingly enough, the TEB is not only the structure with the highest proliferative ratio but also with the lowest percentage of cell loss in comparison with other parenchymal structures ( Table 7) . The rate of cell loss is very high in the lobular structures present in the mammary gland of parous rats. This dearly indicates that the TEB of the young virgin female is the truly proliferating structure of the gland that reaches a steady state only after acquiring fill differentiation. The (60) . These differences in the length of Tc are mainly due to differences in the length of the G1 phase of the cell cycle, whereas all the other phases remain constant (60 Differentiation. Mammary cancer in experimental models is the result of the interaction of a carcinogen with the target organ, the mammary gland. This target, however, is extremely complex because the mammary gland does not respond to the carcinogen as a whole, but only specific structures within the gland are affected by given genotoxic agents. The knowledge of the architecture and cell kinetic characteristics of the mammary gland at the time of carcinogen administration constitutes a necessary initial step for understanding the pathogenesis of the disease. It is also required for distinguishing those changes induced by the carcinogen from changes reflecting normal gland development, especially when evaluating early tumorigenic response in short term studies (15) (16) (17) (18) (19) 22, 55, 145) .
The susceptibility of the mammary gland to DMBA-or MNU-induced carcinogenesis is strongly age dependent; it is maximal when the carcinogens are administered to virgin females between the ages of 40 to 60 days, that is, soon after vaginal opening and during early sexual maturity (14, 15, 162) . Active organogenesis and a high rate of proliferation of the glandular epithelium are characteristics of this period in which there is also high DMBA activation (17, 20, 162) . Its significance, however, is uncertain, because MNU, which is also most effective at this age, does not require activation (13, 166) . The incidence of DMBA-induced tumors reaches 100% when the carcinogen is administered to rats aged days, but the highest number of tumors per animal is observed when the carcinogen is given to animals between the ages of 40 and 46 days, coincident with the period in which the mammary gland exhibits a high density of highly proliferating TEBs (18, 20, 22) . This high susceptibility is attributed to the specific characteristics of the mammary gland that prevail during that period of life. Administration of DMBA to virgin rats induces the largest number of transformed foci when TEBs are decreasing in number due to their differentiation into ABs. These structures, instead of differentiating into ABs, become progressively larger due to epithelial proliferation, with multilayering, secondary lumen formation, and early papillary projections to the widened lumen. At this stage, transformed TEBs are called intraductal proliferations (IDPs) Environmental Health Perspectives * Volume 104, Number 9, September 1996 10, Table 9 ). Their confluence leads to the formation of microtumors, which can be classified histologically as intraductal carcinomas. These intraductal carcinomas progress to invasive carcinomas, developing various patterns such as cribriform, comedo, or papillary types (Fig. 10, 11, 12 ) (15, 24) . The histopathological appearance of these lesions is strikingly similar to the neoplasms developed in the human breast; a comparison between human and rat mammary tumors is shown in Table 10 . Even though TEB differentiation into AB is inhibited by carcinogen treatment, not all the TEBs present in the mammary gland at the time of DMBA administration progress to IDPs. Some TEBs still differentiate into ABs, but their number is always lower than that in control animals. Occasional lobular development is observed, although it is negligible. Some TEBs become smaller, exhibiting an atrophic appearance. At this stage, they are called terminal ducts (TDs). TDs are also susceptible to neoplastic transformation and are the main target of carcinogens in older animals (40) . Those TEBs that were already differentiated into ABs and early lobular structures before DMBA administration do not develop carcinomas. Most of them either remain unmodified, undergo dilatation of the lumen and give rise to cystic structures, or exhibit epithelial proliferation and form tubular adenomas (Fig.  12,13 ). When old virgin females ranging in age from 180 to 330 days are inoculated with DMBA, they develop tubular adenomas that exhibit focal areas of malignant transformation, giving origin to well-differentiated adenocarcinomas with a tubular pattern. These lesions develop predominantly in the abdominal glands in which a higher incidence of tumors is observed in older animals. The observation that mammary carcinomas arise from undifferentiated structures of the gland, namely TEBs and TDs, and benign lesions such as adenomas, cysts, and fibroadenomas arise from structures that were more differentiated at the time of carcinogen administration indicates that the carcinogen requires an adequate structural target and the type of lesion induced is dependent upon the area of the mammary gland that the carcinogen affects. Thus, the more differentiated the structure at the time of carcinogen administration, the more benign and organized is the lesion that develops (Fig. 12 ) (15, 22, 24, 167) . The similarities observed between benign lesions developed in the human breast and the rodent mammary gland (Table 10) are indicative of a similarity in their pathogenetic pathways as well.
Cell oforigin ofrat mammary carcinomas. In the rat mammary gland parenchy- ma, three types of epithelial cells have been described (Fig. 3,5 Days after DMBA administration (169 and periodic acid-Schiff (PAS). The increased synthetic activity is evidenced by an increase in uptake of 3H-fucose and 3H-glucosamine (Fig. 19) (81, 86, 158, 178, 179) . To yield valid results, rats fed high fat diets must be compared with rats fed diets that supply sufficient fat for normal growth and development, at least 4 to 5% fat by weight, and sufficient essential fatty acids. The control diet must be equivalent in all nutrient-to-calorie-ratios to the high fat diet. The two groups of rats must show comparable weight gain or controls must be included to permit evaluation of caloric and specific fat effects on tumorigenesis because tumor incidence is increased with increased caloric consumption (180, 181) . Studies of the mechanisms by which fat may act have been reviewed extensively in recent publications (157, 176) . No mechanism other than increased caloric intake has been convincingly demonstrated to contribute to or be responsible for the effect of fat because reduction of caloric intake by 20, 30 or 40% (180) (181) (182) , even with a percentage of calories from fat held at a high level, increases tumor latency and reduces incidence, number, and size of tumors. However, added caloric intake and weight gain by rats fed high fat diets do not account for correlation of increased tumorigenesis with type, as well as amount, of fat (157, 166, (183) (184) (185) (186) (187) or for results of paired-feeding studies (184) .
In DMBA-treated rats in which the energy intake from fat (corn oil) had been doubled from 25 to 48% of calories (from 10.5 to 24.6% by weight) for the 4 weeks between weaning and DMBA administration, mammary tumor incidence increased significantly; the odds ratio for carcinoma increased by a factor of 1.6 and for any tumor by a factor of 5. Body weight and caloric intake over the 4-week period were not affected by dietary fat content, provided that the protein content was adequate for growth. This result and studies using lard in the place of corn oil (157, (184) (185) (186) confirmed an effect of fat on the initiation of tumorigenesis. After DMBA was given, all rats were fed the same diet with 24% of calories as fat; a positive effect of caloric intake on tumor incidence was found to be independent of dietary fat content. The high fat diets that enhance tumorigenesis do not alter significantly: (1) toxicokinetics of DMBA (188); (2) blood levels of PRL, 17P-estradiol, progesterone, or LH or the patterns of hormone secretion through the estrous cycle (185, 186, 189) ; or (3) [3H]thymidine labeling of mammary gland epithelial DNA before or after carcinogen exposure (190) . Although induction of both hormone-dependent and hormoneindependent tumors responds to dietary fat content (185, 186) , high fat diets do not increase the growth rate of tumors as measured by palpation (157, 178) .
The influence of caloric use by voluntary or involuntary exercise is under investigation. Unfortunately, results are variable and show both increased and decreased tumorigenesis in exercised rats (190) . Standardization of methods with measurement of energy intake and expenditure and of body composition are needed to permit comparison and interpretation of results. There is renewed interest in the effect of omega-3 fatty acids on growth and metastasis of transplanted, as well as induced, mammary tumors in rats. However, the results are not entirely consistent within or among laboratories, probably in part because acceptance of the diets by rats varies (191) .
The influence of caffeine on the mammary gland is of interest because of the postulated relationships between coffee consumption and fibrocystic disease or breast cancer, although significant relationships have not been demonstrated in epidemiologic studies. Highly variable responses to coffee and caffeine have been shown in rats and mice (159, 192, 193) . In DMBA-treated Sprague-Dawley rats given coffee or caffeine in drinking water before and during DMBA initiation of mammary tumorigenesis, tumor multiplicity, but not tumor incidence or tumor latency, was reduced in comparison with rats given DMBA alone. When coffee or caffeine were given after DMBA administration, there was no consistent effect on tumorigenesis (192) . Results were the same when rats were fed a purified diet that contained 5 or 20% fat (by weight) (193) . In mice given similar amounts of coffee or caffeine, DMBA-induced or murine mammary tumor virus-induced tumor multiplicity was increased but other parameters of tumorigenesis were not affected. Caffeine increased mammary gland development in mice, apparently by increasing the response to trophic hormones (159) .
Epidemiologic studies strongly indicate that alcohol intake is a risk factor for breast cancer (194, 195) . The increased risk is 1.5-to 3-fold, depending upon the population studied and the amount of alcohol consumed. In experimental animals, alcohol may have an inhibitory effect on the liver metabolism of certain compounds such as nitrosamines that are carcinogenic in a variety of sites. In rats treated with MNU, which does not require metabolic activation, daily doses ofethanol (5 mg/kg body weight) were associated with increased numbers of malignant tumors but not significant alteration of tumor latency or incidence (195) .
Impact of Hormones and Growth Factors in Mammary Carcinogenesis
The role of hormones on the development of the mammary gland has been the subject of numerous studies which over the years have generated a bibliography too voluminous to be comprehensively cited here (66, 101, 196 Pituitary FSH interacts with GH and PRL in modulating ovarian steroidogenesis, a function that is also influenced by epinephrine, which is secreted by the adrenal medulla (68) . The ovary also secretes inhibin and activin, non-steroidal glycoprotein hormones that feed back to the pituitary, specifically in an FSH-release suppression function (70) . The response of the mammary gland to these complex hormonal interactions results in developmental changes that permanently modify the architecture and the biologic characteristics of the gland. The mammary gland, in turn, responds selectively to given hormonal stimuli depending upon specific topographic differences in gland development, which modulate the expression of either cell proliferation or differentiation, as described above.
Ovarian Steroid Hormones and Growth Factors
The ovary secretes three main classes of steroid hormones (estrogens, androgens, and progestins). Their relative and absolute amounts change periodically during the phases of the menstrual cycle in humans and the estrous cycle in rodents. The three main natural estrogenic hormones synthesized by ovarian follicles are estradiol, estrone, and estriol. Estrogens are critically involved in mammary gland development and are also essential for eliciting a tumorigenic response with chemical or physical carcinogens (47, 197) . Estrogens act on mammary epithelial cells through three different mechanisms: a direct receptor-mediated effect, a mammary stroma-mediated effect, and an in vivo stimulation of pituitary PRL levels, which in turn, stimulates lobuloalveolar development in the mammary gland (67, 76) . Estradiol is the most potent and abundant estrogenic hormone and is responsible for the beginning of estrus. It is oxidized in the liver to estrone, which in turn can be hydroxylated to estriol. Estriol decreases the effects of estradiol, thus acting as a partial antagonist. Continuous administration of supraphysiological doses of estrogens, either by implantation of pellets or subcutaneous injection, induces a high percentage of rat mammary tumors, which are predominantly adenocarcinomas (154), whereas low doses given over long periods induce fibroadenomas (198) . The tumorigenic effects of estrogens are dependent on a functional pituitary gland because they are ineffective in hypophysectomized rats (101, 199) . Secondary changes in the pituitary gland have been found in rats after prolonged administration of estrogen. Treatment of female F344 rats with DES causes a 10 to 16-fold enlargement of pituitary glands, an increase in number of hyperplastic PRLsecreting cells that exhibit hyperplasia of the rough endoplasmic reticulum, and decreased secretory granules. Estrogens stimulate the growth of DMBA-and MCAinduced mammary tumors when administered at low doses; however, the development and growth of these adenocarcinomas are inhibited by high doses of 17,-estradiol, estriol, estrone, and DES. This biphasic effect might be explained by the stimulation of PRL secretion by low levels of estrogens, and the inhibition of PRL by large doses (197) . Ovariectomy either prior to or very soon after MCA or DMBA administration suppresses rat mammary carcinoma development; it also inhibits tumor growth or causes tumor regression in rats already bearing tumors. Reactivation of tumor growth in ovariectomized rats can be accomplished by administering moderate levels of 17p-estradiol or DES (101) . The combination of estrogen and PRL is essential for the neoplastic transformation of the mammary epithelium, because no tumors are induced by administration of estrogens following hypophysectomy. Hypophysectomy alone, on the other hand, does cause tumor regression (197) .
Progesterone, one of the main hormones produced by the corpus luteum (200) , when implanted in female rats increases the frequency of both MCA-and DMBA-induced mammary tumors in either intact or ovariectomized rats but does not do so in ovariectomized-adrenalectomized rats (25, 27, 64, 65, (201) (202) (203) (204) (205) . Chronic administration of progesterone to neonatally androgenized rats at varying times after DMBA treatment causes a marked increase in development and growth of mammary carcinomas (101); however, moderate to high doses of this hormone, in combination with high doses of estrogen, inhibit the growth of DMBAinduced rat carcinoma (28) . The latter treatment causes intense hyperplasia in the normal rat mammae and also causes ovarian atrophy. It is curious that a moderate dose level of progesterone, by itself a mammary tumorigen, coupled with estrogen at high dose levels, provides a therapeutic hormonal milieu considerably more effective than treatment with estrogen alone at high doses (12, 28, 101) . It is important that moderate doses of progesterone or estrogen (natural or synthetic) can enhance the growth of polycyclic aromatic hydrocarbon-induced rat mammary carcinomas.
Inhibins are heterodimeric growth factors, members of the transforming growth factor c (TGF-,) superfamily. These glycoprotein hormones are produced in the gonads; their known function is a feedback mechanism to the pituitary for inhibiting the production and release of FSH (69, 70, 85) . The granulosa cells of the ovary in most species and human luteal cells have been identified as the sites of inhibin synthesis in the female. Inhibin mRNA has been detected in extragonadal tissues; recently its synthesis by the rat mammary epithelium in response to human chorionic gonadotropin (hCG) treatment and during pregnancy has been reported (69) . These findings and the observation that inhibin-deficient transgenic mice develop gonadal tumors (206) indicate that this peptide has a tumor suppressor activity, in addition to autocrine or paracrine growth and differentiation modulator functions. Pituitary Hormones Two endocrine bodies, the hypothalamus and the pituitary gland, have a role in the control of prolactin secretion. The anterior pituitary is able to synthesize and release large quantities of prolactin upon the destruction of hypothalamic connections. The hypothalamus inhibits prolactin secretion via production of prolactin-inhibiting factor (PIF), which is in turn controlled by the amount of catecholamines released from nerve endings in the hypothalamus. Rising catecholamine concentrations result in release of PIF and reduced release of prolactin by the pituitary. A decrease in catecholamine release produces the opposite effect. Estrogen acts on the pituitary gland to increase prolactin release and on the hypothalamus to decrease PIF, thus increasing prolactin secretion by dual mechanisms. In addition, the thyroid hormones, acting directly on the pituitary, also increase prolactin secretion (199) . The influence of prolactin on the induction and growth of spontaneous or oncogene-induced mammary neoplasia in rats and mice is well established (207) (208) (209) (210) (211) . Grafting of multiple pituitary isographs to mice significantly increases the incidence of mammary tumors. This same procedure used on nulliparous and multiparous rats greatly increases this tumor incidence over that of the nongrafted controls, regardless of parity status (212) . In the rat, production of median-eminence hypothalamic lesions in females results in a significant increase in spontaneous mammary neoplasia. Such lesions in the rat increase prolactin secretion and decrease or prevent secretion of other anterior pituitary hormones. All of these effects indicate that prolactin is the major pituitary hormone in spontaneous mammary oncogenesis and that an endocrine imbalance can be tumorigenic in the rat and the mouse. There is a direct correlation between prolactin levels in serum and the genetically influenced susceptibility of several rat strains to induced mammary tumorigenesis (213) . The following treatments and physiological states cause hyperprolactinemia in female rats bearing DMBAor MCA-induced mammary tumors and significantly increase growth of these neoplasms: adrenalectomy; pregnancy; pseudopregnancy; pituitary homografts; pituitary tumors; hypothalamic lesions; hypothalamic implants of steroids; certain neuroendocrineinfluencing drugs such as reserpine, perphenazine, and haloperidol; and high dietary fat. Hypoprolactinemia induced by a number of chemicals (e.g., ergot alkaloids, cydic imide derivatives, lysergic acid, ergoline derivatives, L-dopa, pargyline, antirat prolactin serum) causes significant decreases in growth ofinduced tumors (101) . The reduction in serum prolactin levels, which is generally dose related, is associated with an increase in hypothalamic catecholamines and PIF (214, 215 ). An excess of prolactin is often mitogenic in normal rodent mammary tissue and appears to be a critical regulatory hormone for controlling mitotic activity of mammary epithelium (i.e., deficiency causes hypoplastic epithelium and excess results in mammary hyperplasia). Prolactin-induced changes in mammary mitotic activity might influence the susceptibility of the epithelium to chemical, physical, and viral oncogenic agents. Clearly, fluctuations in levels of prolactin influence the growth of mammary tumors in the rat; however, there does not appear to be a correlation between normal range levels of serum prolactin and either fast-or slow-growing mammary tumors (213) . It is possible that variations in oncogene-induced growth might be the result of the sensitivity of mammary tumor cells to prolactin; thus, small changes in prolactin secretion, not detected by serum analysis, could markedly influence tumor cell proliferation. That prolactin is also the key hormone in mouse mammary neoplasia is supported by the observation that treatment with ovine prolactin or reserpine or the induction of hypothalamic lesions greatly increases the incidence of such tumors in this species. In many strains of mice, prolonged above-normal prolactin secretion invariably accompanies an increase in mammary tumors. Treatment of nulliparous C3H/HeJ mice with either 2-bromo-a-ergocryptine or 6-methyl-8-,-ergoline-acetonitrile, both prolactin-suppressing drugs, virtually prevents or sharply reduces mammary tumorigenesis. It appears that prolactin is not only an important hormonal stimulant of mammary tumorigenesis but is essential in the neoplastic transformation of the mouse mammary gland (101, 213) . Prolactin is the principal pituitary hormone in the development, maintenance, and transformation of hyperplastic alveolar nodules (HAN). Prolactin secretion-suppressing substances reduce the number of HANs, as well as the number of mammary tumors. Although prolactin by itself plays an important role in induction and growth of mammary tumors in rodents, it may also act synergistically with other hormones (e.g., estrogens) or by possibly reacting with other host factors. The simultaneous development of mammary tumors and neoplasia of the pituitary has been observed. Pituitary tumors have been known to develop directly as effects of estrogen on pituitary luteotrophs (216) and indirectly by injury of dopaminergic tuberoinfundibular neurons in the basal hypothalamus, which secrete prolactin-inhibiting factor (217) . The uninhibited activity of these neurons with further stimulation by estrogen is the basis of the pituitary tumor development. The high spontaneous pituitary neoplasia in various rat strains is considered to be, at least in part, due to hyperestrogenism in aging females (218) . The estrogen-induced and spontaneous pituitary tumors have been demonstrated to be primarily prolactin secreting. Data seem to substantiate that estrogens are mammary carcinogens in rodents because of their stimulatory effects on prolactin secretion. However, the role of prolactin in the development of breast cancer in women is uncertain (219) .
Placental Hormones and Growth

Factors
The reproductive process, since its initiation, is deeply dependent of hormonal and neural factors. The maternal corpus luteum, which is instrumental in the preparation of the endometrium for implantation, is in turn rescued by the luteotropic hormone chorionic gonadotropin secreted by the primitive trophoblast of the blastocyst within hours of implantation. In women, hCG stimulates the corpus luteum to synthesize progesterone, 17-hydroxyprogesterone, estradiol, inhibin, and relaxin (98) . hCG also stimulates the synthesis of inhibin in the rat corpus luteum (69). Relaxin plays a major role in the maintenance of early pregnacy because it causes the relaxation of the myometrium and, in conjunction with progesterone, reduces spontaneous uterine activity (220) . The corpus luteum constitutes the major source of progestational steroids until the ninth week of gestation when the placenta becomes the sole source of these hormones, as demonstrated by the lack of effect of ovariectomy after the ninth week on the progression of pregnancy. The placenta has evolved in mammals as an efficient mechanism for transporting nutrients to the fetus, excreting waste products into the maternal blood stream, and influencing maternal physiology through the newly secreted placental and fetal hormones. In humans, the placenta becomes fully developed by the end of the first trimester of pregnancy. The functional unit is the chorionic villus, which is composed of an outer layer of trophoblast, the syncytiotrophoblast, and an inner layer, the cytotrophoblast, both arranged around a core of loose connnective tissue traversed by numerous fetal capillaries. The syncytiotrophoblast synthesizes progesterone through hydroxylation and side-chain cleavage of cholesterol. The syncytiotrophoblast also produces and secretes hCG and human placental lactogen (hPL (69, 222) . CG produced by the placenta of rats, mice, and hamsters is structurally similar to human CG (223) (224) (225) (226) .
Insulin
Insulin is a hormone synthesized by the 5 cells of the islets of Langerhans, the endocrine portion of the pancreas (98) . It is produced in the form of a biosynthetic precursor of higher molecular weight, proinsulin. The structure of insulin has been relatively stable throughout evolution, and most mammalian insulins have similar biological potencies in all species (98) . Glucose is the major stimulus for both the synthesis and secretion of insulin. Insulin, in turn, regulates glucose entry in most tissues (227) . It exerts an acute metabolic effect, i.e., glucose tolerance; it also elicits growth responses and evokes late or long-term biological effects (228) . The development, function, and even tumorigenesis of the mammary gland depend on insulin for expression. The mammary gland primordium of the 17-day rat embryo grows and penetrates the mesenchyme in response to insulin (44) . Insulin plays an essential role in the expression of terminal differentiation of the mammary epithelium. Physiological levels of insulin, in the presence of cortisol and prolactin, induce the synthesis of casein by mouse mammary explants in vitro and promote the induction of ca-lactalbumin in cultured rat mammary tissue, even in the absence of glucose in the medium (228) . Insulin or a glucose solution administered to rats bearing DMBA-induced mammary carcinomas significantly increases tumor growth; when these two substances are administered in combination, the treatment produces a much larger tumor growth response (229, 230) . Alloxan diabetes in tumor-bearing rats induces a significant regression of mammary tumors, quantitatively resembling the regression observed with ovariectomy or hypophysectomy. Administration of insulin activates mammary carcinoma growth in intact rats and reactivates growth in regressing tumors in hypophysectomized rats (231, 232) . Studies have shown that insulin plays an important role in regulating tumor estrogen receptors (233) . Insulin has a direct growth-promoting effect on rat mammary carcinoma cells in vitro (232) .
Androgenic Steroids
Androgenic steroids can be classified in two categories: adrenal androgens (androstenedione, 11 -hydroxyandrostenedione, dehydroepiandrosterone, and dehydroepiandrosterone sulfate), and testicular androgens (testosterone) (234) . Testosterone, which is synthesized by the Leydig cells of the testis in most mammalian species, is the major circulating androgen in the male (235) . Endogenous androgen is responsible for the development of sexual dimorphism in mammary development in rodents (44) . During embryonal life, the target tissue for androgen is the mammary mesenchyme, which undergoes condensation under the influence of androgen secreted by the animal's own testes (44) . Before the advent of antiestrogens, androgens were used for the treatment of advanced breast cancer. Androgens display both an estrogenic and an antiestrogenic effect, depending upon the nature of the receptor they activate (236) . There is evidence that androgens behave as full estrogens when they bind to the estrogen receptor. At high concentrations, dehydrotestosterone induces estrogen-specific responses and stimulates the growth of DMBAinduced rat mammary tumors. Other androgens, like the 5-androstene-3, 17,Bdiol metabolite of the adrenal DHEA and 5a androstane-3P, 17p-diol, which have a high affinity for the estrogen receptor, are estrogenic at near physiological concentrations and, through this mechanism, might stimulate the growth of hormone-dependent mammary cells (236) . Androgens exert an antiestrogenic effect through the inhibition of the estrogen-induced increase in progesterone receptor (236) . These various effects could explain the contradictory observations on the effect of androgens on mammary tumorigenesis reported in the literature. DMBA-induced rat mammary tumors, which regress after hypophysectomy and ovariectomy, also regress after treatment with the androgenic steroids testosterone, dihydrotestosterone, 2-methyldihydrotestosterone propionate, various enol derivatives of dihydrotestosterone, dromostanolone propionate, and 2-methyl-17p-hydroxy-5a-androstan-3-one (25, 27, (237) (238) (239) (240) (241) . When moderate to high doses of androgenic steroids are given to rats with DMBAinduced tumors, an occasional mammary neoplasm is often enhanced, perhaps owing to partial conversion of the androgenic steroids to estrogenic agonists (101, 240 (243) . Alterations in thyroid function, namely hypothyroidism, have been associated with a greater incidence of breast cancer (244) (245) (246) (247) . A statistically significant linear trend in the odds ratio for breast cancer has been found in women with subnormal levels of circulating free thyroxine (T4) with long duration of ovulatory activity (248) and in women receiving thyroid medication for fertility problems (249) ; an excess in numbers of deaths from breast cancer has been reported in women with nontoxic nodular goiter (250) . However, the number of studies is insufficient for drawing definitive conclusions on this relationship, and not all the studies support these conclusions (246, 247) .
In rodent models it has been found that thyroid hormones have a direct effect on growth and differentiation of the mammary gland (243) (244) (245) (246) (247) . This effect is attributed in part to the induction of an increased sensitivity of the tissues to estradiol and prolactin through modulation of the number and the affinity characteristics of their respective receptors (247) . Hypothyroidism in mice is associated with delayed lobuloalveolar development and a greater degree of postlactational involution of the mammary gland. Hyperthyroidism leads to increased development of the mammary tissue; however, it does not affect the postlactational phase of mammary gland regression (244) (245) (246) (247) . The fact that thyroid function also affects pituitary and ovarian function makes it difficult to determine the specific effects of thyroid hormone excess or insufficiency on mammary gland development and carcinogenesis. Studies performed in primiparous mice, made mildly hypothyroid by ingestion of thiouracil or mildly hyperthyroid by administration of thyroxine have revealed that the estrous cycles remain normal, and the levels of prolactin and the morphology and degree of mammary gland development in both groups of animals are similar to those of euthyroid animals. However, the incidence of spontaneous tumors is significantly lower in the hypothyroid animals at 1 year after removal of the pups (246, 247) . It is not clear whether thyroid hormones have a positive or a negative influence on mammary gland development and on carcinogen-induced mammary carcinomas in the rat (247) . Conflicting results include the improved mammary gland development in castrated or estrogen-treated castrated rats after thyroidectomy. These effects were counteracted by T4 administration. These observations suggest that the hypothyroid condition increases the sensitivity of the mammary glands to estrogens (247) . With (Fig. 12) . The undifferentiated lobule type 1 of the human breast has also the highest proliferative activity and in vitro binding of the carcinogen to the DNA and, more importantly, it expresses phenotypes of cell transformation after this treatment. These data indicate that in both rodents and humans the compartment in which the target or stem cell is found is the determinant factor in the initiation event.
Several factors regulate the susceptibility of the stem cells to neoplastic transformation, namely, the topographic location of the mammary gland, age, and reproductive history of the host. Epidemiologic findings support this concept, because a higher incidence of breast carcinoma has been reported in nulliparous women and in women having an early menarche, factors that are indicative of a higher susceptibility to breast cancer, which is also coincident with the higher susceptibility to carcinogens observed in young virgin rats due to the presence of undifferentiated structures in the mammary tissue such as TEBs (Fig. 25) . Thus, the protection afforded by early pregnancy and late menarche in humans or by pregnancy or treatment with pregnancy-related hormones such as hCG in rodents drives the mammary gland irreversibly towards the differentiation pathway (Fig. 25) instead of the neoplastic transformation pathway (Fig. 26) (259) . However, epidemiological studies are limited because observations on the end effects of given physical or chemical agents may be performed several years after exposure and only relatively high risks will be detected. One additional problem is that epidemiologic data reveal historical exposures but do not provide information on the potential risk of new or untested chemicals.
The need to evaluate health risks associated with toxic chemical exposure has led to the development of risk assessment as an organized approach for 1) hazard identification for toxic chemicals and potential health effects that might occur in exposed populaVolume 104, Number 9, September 1996 * Environmental Health Perspectives I Figure 26 . Terminal end buds (TEB) evolve to alveolar buds (AB) or lobules if pregnancy or human chorionic gonadotropin (hCG) stimulate them towards the differentiation pathway. If a carcinogen reaches the target (TEB) during the susceptibility period, it diverts this evolution to the neoplastic transformation pathway, developing instead into intraductal proliferation (IDP), intraductal carcinoma (IDCa), and invasive adenocarcinoma (AdCa). From Russo and Russo (41). tions; 2) dose-response modeling; 3) exposure assessment; and 4) risk characterization. In 1976, the U.S. Environmental Protection Agency (EPA) adopted risk assessment and risk management as a twostep process for evaluating risk and policy development for reduction of exposure, respectively (7) . The use of rodent animal models for hazard identification has proven to be useful for carcinogenicity testing. Rodent models are advantageous because they are informative in the absence of human data, they allow the assessment of risk, testing of dose effects, and the characterization of risk; however, the extrapolation of carcinogenic data obtained in rodents to human risk requires us to address basic concerns when evaluating unknown chemicals. First, it needs to be determined whether a tumorigenic response elicited in a rodent model by a specific treatment is a credible indicator for potential human risk. Proper statistical evaluation and mathematical analysis are required for determining the predictive value of a treatment-induced tumorigenic response (261) . The assessment of the carcinogenic potential of an unknown agent requires the use of a model in which the multifactorial conditions that affect a human being during interaction with a given chemical are reproduced. This requirement should be better fuffilled by in vivo than by in vitro models. The ideal condition would be a model in which an animal is subjected to the same conditions as the human, for example, household pets.
Cats that develop spontaneous mammary carcinomas which metastasize, like in humans (50) , and dogs that develop mammary cancer in response to progestogens (49) have been proposed as adequate models. Monkeys, which are more similar to humans than any other species in menstrual cyclicity and endocrinologic conditions (51) , should represent the optimal model; however, time, space, and economical restraints have hindered the wider use of these models in favor of the more economical rodent models. Rodent models of chemically induced mammary carcinogenesis have provided valuable information on the optimal host conditions, as well as on dose and route of administration to be utilized for eliciting maximal tumorigenic response (12) (13) (14) (15) (16) (17) (18) (19) (20) (25) (26) (27) (28) (29) . Knowledge gained through the study of these models has allowed researchers to determine that tumor incidence, number of tumors per animal, tumor type, and latency period of chemically induced mammary neoplasms are dose dependent, as well as dependent upon the age and reproductive history of the animal at the time of carcinogen exposure (12) (13) (14) (15) (16) (17) (18) (19) (20) (25) (26) (27) (28) (29) 52 ). Because known genotoxic agents are highly tumorigenic when given to young animals and the induced mammary neoplasms have a short latency period, the background induced incidence of spontaneous mammary tumors in rodents, which, although variable, develops late in life, becomes less relevant. These models have allowed researchers to test the influence of dose in the tumorigenic response. Carcinogen dose has been found to inversely affect tumor latency and directly affect the overall tumor incidence and number of tumors per animal; this effect has been observed exclusively for malignant but not for benign tumors (32) . Thus, it can be concluded that treatment-related increases in the incidence and number of mammary carcinomas per animal are dose dependent, rather than a reflection of the maximum tolerated dose (MTD) used for routine toxicity testing.
Studies of normal mammary gland development and chemically induced rodent mammary carcinogenesis have provided useful information for clarifying how the interplay of ovarian, pituitary, and placental hormones, while influencing the development and physiology of the mammary gland, modulate its response to given chemical carcinogens (12-22,25-29, 38-42,64-66). Rodent experimental models have been useful for testing the hormone dependence of mammary tumors. Although the role played by the most important endogenous hormones in the development, progression, and regression of rodent mammary neoplasia has been fairly well characterized (43, 101, (244) (245) (246) (247) , the fact that they are essential elements in normal body functions implies a no-adverse effect level threshold for the normal effects and the interplay of feedback mechanisms (262) . Hormones may not be carcinogenic in themselves, but they may allow the neoplastic transformants initiated by proximal carcinogens to establish and grow by modifying the host or target tissue (115) (27, (18) (19) (20) (21) (22) , whereas the direct-acting MNU has to be rapidly injected intravenously (12) (13) (14) 101) . The fact that topical applications of DMBA in the mammary gland and intraperitoneal injections of MNU elicit a tumorigenic response indicates that alternative routes may also be indicative of the carcinogenic potential of a given substance. However, the large variability in tumorigenic response reported by different laboratories using identical carcinogens, doses, and routes and even intralaboratory variations makes it difficult to generalize on the appropriateness of route selection for carcinogenic testing and risk assessment. Despite these concerns, careful comparisons of the pathogenesis and histopathology of mammary cancer in humans and rodents have provided a reliable basis for extrapolating carcinogenic data from experimental models to the human condition (23, 24) .
Conclusions and Future Directions
This work describes and compares experimental in vivo models presently used for assessing the mammary carcinogenic potential of given chemical and physical agents and addresses the need for identifying those models that provide information on the mechanisms involved in cancer initiation and progression in the human population. The main problems identified in this study are the complexity and multistep nature of the carcinogenic process, the lack of understanding of the mechanism(s) involved in the initiation and progression of the disease, and the lack of identification of a specific etiologic agent or agents of human breast cancer. Long-term studies in rodent models have been traditionally used, mainly due to the susceptibility of the rodent mammary gland to develop both spontaneous and chemically induced neoplasms. The usefulness of chemically induced mammary tumors lies in their hormone dependence; the high frequency of adenocarcinomas histologically similar to human breast cancers; the possibility they offer for analyzing the initiation, promotion, and progression steps of carcinogenesis; and the baseline information they provide in risk assessment. Classical studies of these models have allowed researchers to identify the optimal host conditions, as well as the dose and route of administration to be used for eliciting maximal tumorigenic response. Chemically induced mammary tumors develop by a multistep process, which begins as a biochemical lesion caused by the interaction of the carcinogen with cellular DNA. In this interaction, the DNA is damaged and, if the damage is not repaired efficiently, the result is a mutation, chromosomal translocation, inactivation of regulatory genes, or more subtle changes that are not yet well identified. Neoplastic development requires that the lesion becomes fixed, aided by cell proliferation, and progresses to a third stage of autonomous growth, which results in cancer when the lesion acquires the capacity to invade and metastasize. Several carcinogens such as MCA, DMBA, and MNU have been extensively studied in mice and rats. DMBA and MNU have been the most frequently used; the majority of the mammary tumors induced in rats by either one of these agents are hormonedependent adenocarcinomas. The observation that maximal tumor incidence is elicited when the carcinogens are administered to young virgin female rats has led to important discoveries on the role of mammary gland development and differentiation in cancer initiation. Hormonally induced differentiation and the interplay of ovarian, pituitary, and placental hormones have been identified as powerful modulators of the tumorigenic response elicited by genotoxic chemicals.
Humans and all living species are exposed either acutely or chronically to numerous physical and chemical agents that can cause health hazards. The human population is exposed to a large number of environmental chemicals such as polycyclic aromatic hydrocarbons, nitrosoureas, and aromatic amines that are known to be carcinogenic in in vivo experimental animal models and are known to induce mutagenesis and neoplastic transformation of mammary cells in in vitro models. The potential of chemicals to induce cancer in humans has been recognized for over two centuries. The identification of specific physical and chemical agents such as radiation, coal tar, and benzene as causes of human cancers and leukemias has led to the classification of some agents as known human carcinogens (EPA Class A, IARC Class I). The demonstration that these agents can be mutagenic or carcinogenic in experimental systems has constituted the basis for developing biomarkers for monitoring human exposure. The knowledge of the health effects of these known carcinogens has led OSHA to adopt specific requirements for risk assessment, biomonitoring, and adoption of safety levels of exposure (7) . Confirmation of these effects through epidemiological studies, however, is limited because observations on the end effects of given physical or chemical agents might be performed several years after exposure and only relatively high risks will be detected. Because epidemiological data reveal historical exposures but do not provide information on the potential risk of new or untested chemicals, experimental animal models should provide the necessary information for accurately predicting the human carcinogenic potential of a given substance. The utilization of rodent animal models for hazard identification has proven to be useful for carcinogenicity testing. Rodent models are advantageous because they are informative in the absence of human data, they allow the assessment of risk, the testing of dose effects and the characterization of risk. However, the extrapolation of carcinogenic data obtained in rodents to human risk requires basic concerns be addressed when evaluating unknown chemicals. First, it should be determined whether a tumorigenic response elicited in a rodent model by a specific treatment is a credible indicator for potential human risk. Proper statistical evaluation and mathematical analysis are required for determining the predictive value of a treatment-induced tumorigenic response. The assessment of the carcinogenic potential of an unknown agent requires the use of a model in which the multifactorial conditions that affect a human being during interaction with a given chemical are occurring. The relevance of experimental animal models should be validated by careful comparisons with the human condition. The greater the similarities between the two systems, the greater the predictive value and the validity of extrapolations from rodents to humans (263) (264) (265) (266) .
